Anagrelide

Research use only, not for human use.

Anagrelide is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor.

Anagrelide is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor.

Cell Proliferation Assay Cell Line:Megakaryocytic and non-megakaryocytic cellsConcentration:0.05, 0.3, 1 μM Incubation Time:12-day Result:Inhibited only megakaryocytic cell growth at every concentration testedCell Cytotoxicity Assay Cell Line:GIST882 and GIST48 cell line Concentration:0.1, 1, 10, 100, 1000, 10000 nM Incubation Time:Result:Induced a cytotoxic effect in the GIST882 cell line (IC50= 16 nM), but was only weakly active in the GIST48 cell line.

Animal Model:Adult female athymic mice bearing GIST2B, GIST3, GIST9, GIST882 model Dosage:5 mg/kg Administration:Twice daily; for 10 days Result:Inhibited or reduced tumor growth in three (GIST2B, GIST9, GIST882) of these four models.

Agrelin | Agrylin | Anagrelide | Anagrelide | BL 4162A | Xagrid | Shire | Thromboreductin

Angiogenesis

PDE

PDE

Cardiovascular Disease

——

68475-42-3

256.09

C10H7Cl2N3O

>98% (HPLC)

DMSO: 10 mM

C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31

6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one

(-20℃)

With Ice Pack

≥ 2 years